![](https://monteverdelaw.com/wp-content/uploads/case-logo/rayzebio-inc.jpg)
RayzeBio, Inc. (Nasdaq: RYZB), relating to its proposed sale to Bristol-Myers Squibb Co. Under the terms of the agreement, RYZB shareholders are expected to receive $62.50 in cash per share they own.
RayzeBio, Inc. (Nasdaq: RYZB), relating to its proposed sale to Bristol-Myers Squibb Co. Under the terms of the agreement, RYZB shareholders are expected to receive $62.50 in cash per share they own.